Skip to content
PubMed This is a summary of 69 peer-reviewed journal articles Updated
Hematology

Familial thrombomodulin anomalies: A Patient Guide

At a Glance

Familial thrombomodulin anomalies are rare inherited THBD conditions that may cause serious bleeding despite normal routine tests or increase the risk of small-vessel clots and kidney injury through aHUS. The specific variant helps determine the risk pattern and care plan.

Familial thrombomodulin anomalies are exceptionally rare inherited conditions that disrupt the body’s delicate balance between bleeding and clotting. At the heart of this condition is a mutation in the THBD gene, which provides instructions for making thrombomodulin, a protein that sits on the lining of your blood vessels and helps regulate blood clotting and the immune system’s complement pathway. Because this protein is involved in multiple complex systems, a single “typo” in its genetic code can lead to a medical paradox: depending on the exact nature of the mutation, a person may face a severe risk of uncontrollable bleeding or, conversely, a dangerous tendency toward clotting and kidney damage [1][2].

In cases where the mutation causes a “bleeding phenotype,” known as Thrombomodulin-Associated Coagulopathy (TM-AC), the body may produce an overabundance of a floating form of the protein that prevents blood from clotting effectively. This version of the condition is particularly challenging because routine laboratory tests used in standard medical settings often come back entirely normal, even when a significant bleeding risk is present [1][3]. On the other hand, different mutations can impair the protein’s function, leaving the body unable to “turn off” the clotting process. This can act as a susceptibility factor for Atypical Hemolytic Uremic Syndrome (aHUS), where tiny clots form in small blood vessels throughout the body, often affecting the kidneys [4][2].

Because these anomalies are so rare, most of what is known comes from studying a small number of families around the world rather than large clinical trials. This means that living with the condition requires a highly personalized approach to care, often involving a team of specialists who understand the complex relationship between your genetics and your blood’s behavior. Understanding whether your specific mutation causes a “gain” or “loss” of protein function is the most critical step in navigating high-risk events like surgery, trauma, or pregnancy. By working with a specialized team, you can move beyond the confusion of this rare diagnosis and build a proactive plan to manage your health safely [1][5].

What Your Result Means

  • THBD-associated TM-AC: A confirmed bleeding disorder needing an individualized surgical plan. Routine PT/aPTT are often normal.
  • THBD-associated aHUS: A genetic susceptibility to complement-mediated microscopic clotting.
  • VUS (Variant of Uncertain Significance): An unclear result that does not prove disease and should not be used for predictive family testing without expert guidance.

Common questions in this guide

How can a THBD mutation affect my health?
A change in the THBD gene can alter thrombomodulin, a protein that helps regulate blood clotting and the immune complement system. Depending on the variant, it may be associated with a bleeding disorder called thrombomodulin-associated coagulopathy (TM-AC) or with susceptibility to atypical hemolytic uremic syndrome (aHUS), which can cause small-vessel clots and kidney injury.
Can normal PT and aPTT tests rule out bleeding risk from a THBD variant?
No. People with THBD-associated TM-AC may have a significant bleeding risk even when routine PT and aPTT results are normal. Specialists may consider tests such as thrombin generation or soluble thrombomodulin levels along with the genetic result and bleeding history.
What does a VUS in THBD mean?
A variant of uncertain significance (VUS) is a genetic change whose effect is not yet clear. It does not prove that you have a THBD-related disorder and should not be used alone for predictive testing of relatives without guidance from a genetics professional.
What is the difference between TM-AC and THBD-associated aHUS?
TM-AC is the bleeding branch, in which an excess floating form of thrombomodulin can interfere with effective clotting. THBD-associated aHUS is the clotting branch, in which impaired thrombomodulin function may allow tiny clots to form in small blood vessels, often affecting the kidneys.
How should my family members be evaluated for a THBD variant?
Family testing should be based on the specific variant found in the affected relative and guided by a medical genetics professional. A confirmed disease-causing variant may support targeted testing of relatives, while a VUS should not be used for predictive testing without expert interpretation.
What should I do before surgery, trauma, or pregnancy if I have a THBD anomaly?
High-risk events such as surgery, trauma, and pregnancy should be discussed with a specialized team so an individualized safety plan is available. Because routine PT and aPTT may be normal in TM-AC, a normal result does not necessarily mean there is no bleeding risk.

Get notified when new evidence is published on Familial thrombomodulin anomalies.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (5)
  1. 1

    A new pedigree with thrombomodulin-associated coagulopathy in which delayed fibrinolysis is partially attenuated by co-inherited TAFI deficiency.

    Westbury SK, Whyte CS, Stephens J, et al.

    Journal of thrombosis and haemostasis : JTH 2020; (18(9)):2209-2214 doi:10.1111/jth.14990.

    PMID: 32634856
  2. 2

    Functional assessment of genetic variants in thrombomodulin detected in patients with bleeding and thrombosis.

    Van Laer C, Lavend'homme R, Baert S, et al.

    Blood 2025; (145(17)):1929-1942 doi:10.1182/blood.2024026454.

    PMID: 39841007
  3. 3

    A case of thrombomodulin mutation causing defective thrombin binding with absence of protein C and TAFI activation.

    Okada M, Tominaga N, Honda G, et al.

    Blood advances 2020; (4(12)):2631-2639 doi:10.1182/bloodadvances.2019001155.

    PMID: 32556284
  4. 4

    Nephrotic-Range Proteinuria and Peripheral Edema in a Child: Not Only Idiopathic Nephrotic Syndrome.

    Dolcemascolo V, Vivarelli M, Colucci M, et al.

    Case reports in nephrology and dialysis 2016; (6(3)):120-127 doi:10.1159/000449423.

    PMID: 27904864
  5. 5

    How to investigate mild to moderate bleeding disorders and bleeding disorder of unknown cause.

    Casini A, Gebhart J

    International journal of laboratory hematology 2024; (46 Suppl 1()):27-33 doi:10.1111/ijlh.14266.

    PMID: 38454298

This page explains inherited THBD-related bleeding and clotting risks for educational purposes and does not replace medical advice. A hematologist, geneticist, or other specialist should interpret your variant and help plan care.